Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : INT301
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Intrommune Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Intrommune Therapeutics Strikes Deal with Circuit Clinical®
Details : Based on this deal, Circuit Clinical will oversee the early clinical development of Intrommune’s lead drug, INT301, including a Phase 1b study planned for Q4 2020 and Q1 2021.
Product Name : INT301
Product Type : Protein
Upfront Cash : Undisclosed
October 20, 2020
Lead Product(s) : INT301
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Intrommune Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement